HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

A pan-inhibitor of DASH family enzymes induces immune-mediated regression of murine sarcoma and is a potent adjuvant to dendritic cell vaccination and adoptive T-cell therapy.

Abstract
Multimodality therapy consisting of surgery, chemotherapy, and radiation will fail in approximately 40% of patients with pediatric sarcomas and result in substantial long-term morbidity in those who are cured. Immunotherapeutic regimens for the treatment of solid tumors typically generate antigen-specific responses too weak to overcome considerable tumor burden and tumor suppressive mechanisms and are in need of adjuvant assistance. Previous work suggests that inhibitors of DASH (dipeptidyl peptidase IV activity and/or structural homologs) enzymes can mediate tumor regression by immune-mediated mechanisms. Herein, we demonstrate that the DASH inhibitor, ARI-4175, can induce regression and eradication of well-established solid tumors, both as a single agent and as an adjuvant to a dendritic cell (DC) vaccine and adoptive cell therapy (ACT) in mice implanted with the M3-9-M rhabdomyosarcoma cell line. Treatment with effective doses of ARI-4175 correlated with recruitment of myeloid (CD11b) cells, particularly myeloid DCs, to secondary lymphoid tissues and with reduced frequency of intratumoral monocytic (CD11bLy6-CLy6-G) myeloid-derived suppressor cells. In immunocompetent mice, combining ARI-4175 with a DC vaccine or ACT with tumor-primed T cells produced significant improvements in tumor responses against well-established M3-9-M tumors. In M3-9-M-bearing immunodeficient (Rag1) mice, ACT combined with ARI-4175 produced greater tumor responses and significantly improved survival compared with either treatment alone. These studies warrant the clinical investigation of ARI-4175 for treatment of sarcomas and other malignancies, particularly as an adjuvant to tumor vaccines and ACT.
AuthorsBrynn B Duncan, Steven L Highfill, Haiying Qin, Najat Bouchkouj, Shannon Larabee, Peng Zhao, Iwona Woznica, Yuxin Liu, Youhua Li, Wengen Wu, Jack H Lai, Barry Jones, Crystal L Mackall, William W Bachovchin, Terry J Fry
JournalJournal of immunotherapy (Hagerstown, Md. : 1997) (J Immunother) Vol. 36 Issue 8 Pg. 400-11 (Oct 2013) ISSN: 1537-4513 [Electronic] United States
PMID23994886 (Publication Type: Journal Article, Research Support, N.I.H., Intramural)
Chemical References
  • ARI-4175
  • Adjuvants, Immunologic
  • Boron Compounds
  • Cancer Vaccines
  • Dipeptides
  • Dipeptidyl-Peptidase IV Inhibitors
Topics
  • Adjuvants, Immunologic (administration & dosage)
  • Adoptive Transfer
  • Animals
  • Boron Compounds (administration & dosage, therapeutic use)
  • Cancer Vaccines (administration & dosage)
  • Cell Line, Tumor
  • Combined Modality Therapy
  • Dendritic Cells (immunology, transplantation)
  • Dipeptides (administration & dosage, therapeutic use)
  • Dipeptidyl-Peptidase IV Inhibitors (administration & dosage, adverse effects)
  • Female
  • Immunologic Memory
  • Mice
  • Mice, Inbred C57BL
  • Rhabdomyosarcoma (immunology, therapy)
  • T-Lymphocytes (immunology, transplantation)
  • Tumor Burden (drug effects)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: